Research Article| Volume 283, ISSUE 1-2, P207-210, August 15, 2009

Treatment of dementia and cognitive impairment: What can we learn from the Cochrane Library

Published:March 09, 2009DOI:



      Systematic reviews of health care interventions in a single database have great practical value.


      We analyze the dementia related information in the Cochrane Library.


      In 2008 the Cochrane Library has over 5300 systematic reviews, and in the latest — 2008/3 — issue over 100 reviews have the term “dementia” in their title, abstract or keywords. The Cochrane Dementia and Cognitive Improvement Group has a major role in preparing systematic reviews of randomized clinical trials in the field of dementia. Pharmacological as well as non-pharmacological interventions are analyzed. The reviews are prepared by strict methodology and have uniformed, organized structure. Cochrane reviews or at least their abstracts are available free of charge at About an intervention a review may find evidence of benefit, evidence of harm, or evidence of no effect. For several interventions there is not enough evidence of effect — due to lack of information or if the studies are not conclusive, further research is recommended. In addition to systematic reviews the Cochrane Library includes a large database of bibliographic data of randomized controlled trials, technology assessments and economic evaluations.


      The use of this source of information is strongly recommended for all who are involved in patient care or health care policy.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. World Health Organization. International Classification of Diseases — ICD-10, Version 2007. URL: Accessed: January 2, 2008.

        • Launer L.J.
        • Andersen K.
        • Dewey M.E.
        • Letenneur L.
        • Ott A.
        • Amaducci L.A.
        • et al.
        Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia.
        Neurology. 1999; 52: 78-84
        • Kalache A.
        • Keller I.
        The greying world: a challenge for the twenty-first century.
        Sci Prog. 2000; 83: 33-54
      2. United States National Library of Medicine. PubMed. URL: Accessed: January 2, 2008.

        • Baskys A.
        • Hou A.C.
        Vascular dementia: pharmacological treatment approaches and perspectives.
        Clin Interv Aging. 2007; 2: 327-335
        • Omerovic M.
        • Hampel H.
        • Teipel S.J.
        • Buerger K.
        Pharmacological treatment of Alzheimer's dementia: state of the art and current dilemmas.
        World J Biol Psychiatry. 2008; 9: 69-75
        • Sink K.M.
        • Holden K.F.
        • Yaffe K.
        Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
        JAMA. 2005; 293: 596-608
        • Waldemar G.
        • Dubois B.
        • Emre M.
        • Georges J.
        • McKeith I.G.
        • Rossor M.
        • EFNS
        • et al.
        Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline.
        Eur J Neurol. 2007; 14: e1-e26
        • Szatmári S.
        • Whitehouse P.J.
        Vinpocetine for cognitive impairment and dementia.
        Cochrane Database Syst Rev. 2003; (Art. No.: CD003119)
      3. Szatmári S, Bereczki D. Procaine treatments for cognition and dementia. Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD005993, doi:10.1002/14651858.CD005993.pub2.

        • Yan H.
        • Li L.
        • Tang X.C.
        Treating senile dementia with traditional Chinese medicine.
        Clin Interv Aging. 2007; 2: 201-208
        • Huang Y.
        • Lai X.S.
        • Tang A.W.
        Comparative study of the specificities of needling acupoints DU20, DU26 and HT7 in intervening vascular dementia in different areas in the brain on the basis of scale assessment and cerebral functional imaging.
        Chin J Integr Med. 2007; 13: 103-108
        • Purandare N.
        • Swarbrick C.
        • Fischer A.
        • Burns A.
        Cholinesterase inhibitors for Alzheimer's disease: variations in clinical practice in the north-west of England.
        Int J Geriatr Psychiatry. 2006; 21: 961-964
        • Ramassamy C.
        • Longpré F.
        • Christen Y.
        Ginkgo biloba extract (EGb 761) in Alzheimer's disease: is there any evidence?.
        Curr Alzheimer Res. 2007; 4: 253-262
        • Dos Santos-Neto L.L.
        • de Vilhena Toledo M.A.
        • Medeiros-Souza P.
        • de Souza G.A.
        The use of herbal medicine in Alzheimer's disease—a systematic review.
        Evid. Based Complement. Altern. Med. 2006; 3: 441-445
        • Kennedy D.O.
        • Scholey A.B.
        The psychopharmacology of European herbs with cognition-enhancing properties.
        Curr Pharm Des. 2006; 12: 4613-4623
        • Cochrane A.L.
        1931–1971: a critical review, with particular reference to the medical profession.
        in: Medicines for the year 2000. Office of Health Economics, London1979: 1-11
      4. The Cochrane Library, Issue 3. Wiley, Chichester2008
        • McShane R.
        • Collins H.
        Cochrane Dementia and Cognitive Improvement Group.
        About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2008 (Issue 2. Art. No.: DEMENTIA)
      5. Higgins J.P.T. Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Collaboration. 2008 (Available from
        • Malouf R.
        • Birks J.
        Donepezil for vascular cognitive impairment.
        Cochrane Database Syst Rev. 2004; (Art. No.: CD004395)
        • Craig D.
        • Birks J.
        Rivastigmine for vascular cognitive impairment.
        Cochrane Database Syst Rev. 2004; (Art. No.: CD004744)
        • McShane R.
        • Areosa Sasstre A.
        • Minakaran N.
        Memantine for dementia.
        Cochrane Database Syst Rev. 2006; (Art. No.: CD003154)
        • Tabet N.
        • Feldman H.
        Indomethacin for Alzheimer's disease.
        Cochrane Database Syst Rev. 2002; (Art. No.: CD003673)
        • Jones R.
        • Laake K.
        • Oeksengaard A.R.
        D-cycloserine for Alzheimer's disease.
        Cochrane Database Syst Rev. 2002; (Art. No.: CD003153)
        • Scott H.D.
        • Laake K.
        Statins for the prevention of Alzheimer's disease.
        Cochrane Database Syst Rev. 2001; (Art. No.: CD003160)
        • Birks J.
        • Grimley Evans J.
        Ginkgo biloba for cognitive impairment and dementia.
        Cochrane Database Syst Rev. 2007; (Art. No.: CD003120)